Robert Lafyatis, MD
Following residency training in Internal Medicine at the Bowman Gray School of Medicine, Dr. Lafyatis began his research career studying fibroblast biology and the molecular biology of TGFβ at the National Institutes of Health. After further post-doctoral training at the Pasteur Institut in France and University of North Carolina, he joined the Boston University Medical Center Scleroderma program in 1995. Working with the late Dr. Korn, Dr. Simms, Dr. Farber and Dr. Trojanowska, he has developed a strong translational research program examining the pathogenesis and treatment of systemic sclerosis. This program places a strong emphasis on identifying biomarkers in patients with systemic sclerosis. This research is designed to better understand fibrotic, immunologic and vascular abnormalities that lead systemic sclerosis and its complications, such as pulmonary arterial hypertension and interstitial lung disease. These biomarker studies have shed important light on pathogenesis, but also have been applied successfully to early phase clinical trials allowing more complete and informative assessments of therapeutic effects and responses.
Institution: Boston University School of Medicine
Medical School: University of Cinncinnati College of Medicine/MD/1983
Academic Rank: Professor of Medicine
Mailing address: 72 East Concord Street, E-5, Boston, MA 02118
Summary of academic interest: Investigating pathogenic mechanisms in systemic sclerosis and applying molecular approaches to translational studies.
CORT Project Summaries: CORT Director; Administrative Core PI; Project 1 PI
Recent publications relevant to the CORT:
Elevated expression of cav-1 in a subset of SSc fibroblasts contributes to constitutive Alk1/Smad1 activation. Haines P, Hant FN, Lafyatis R, Trojanowska M, Bujor AM. J Cell Mol Med. 2012 Sep;16(9):2238-46. doi: 10.1111/j.1582-4934.2012.01537.x. PMID: 22277251.
Intrinsic gene expression subsets of diffuse cutaneous systemic sclerosis are stable in serial skin biopsies. Pendergrass SA, Lemaire R, Francis IP, Mahoney JM, Lafyatis R, Whitfield ML. J Invest Dermatol. 2012 May;132(5):1363-73. doi: 10.1038/jid.2011.472. Epub 2012 Feb 9. PMID: 22318389.
Connective tissue disease: SSc-fibrosis takes flight with Wingless inhibition. Lafyatis R. Nat Rev Rheumatol. 2012 Aug;8(8):441-2. doi: 10.1038/nrrheum.2012.99. Epub 2012 Jul 3. PMID: 22751566.
Acid sphingomyelinase deficiency contributes to resistance of scleroderma fibroblasts to Fas-mediated apoptosis. Samuel GH, Lenna S, Bujor AM, Lafyatis R, Trojanowska M. J Dermatol Sci. 2012 Sep;67(3):166-72. doi: 10.1016/j.jdermsci.2012.06.001. Epub 2012 Jun 26. PMID: 22771321.
New insights into the mechanisms of innate immune receptor signalling in fibrosis. Lafyatis R, Farina A. Open Rheumatol J. 2012;6:72-9. doi: 10.2174/1874312901206010072. Epub 2012 Jun 15. PMID: 22802904.
Modeling innate immunity in murine skin: utilization of subcutaneous osmotic pumps for inflammatory and fibrotic skin disease. Dimarzio M, Farina G, Lafyatis R. Methods Mol Biol. 2012;900:317-26. doi: 10.1007/978-1-60761-720-4_15. PMID: 22933076.
Ciprofloxacin has antifibrotic effects in scleroderma fibroblasts via downregulation of Dnmt1 and upregulation of Fli1. Bujor AM, Haines P, Padilla C, Christmann RB, Junie M, Sampaio-Barros PD, Lafyatis R, Trojanowska M. Int J Mol Med. 2012 Dec;30(6):1473-80. doi: 10.3892/ijmm.2012.1150. Epub 2012 Oct 5. PMID: 23041765.
Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor-β Responses: A Novel Mechanism for Maintaining and Amplifying Fibrosis in Scleroderma. Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pope RM, Budinger GR, Mutlu GM, Lafyatis R, Radstake T, Feghali-Bostwick C, Varga J. Am J Pathol. 2013 Jan;182(1):192-205. doi: 10.1016/j.ajpath.2012.09.007. Epub 2012 Nov 7. PMID: 23141927.
p300 Is Elevated in Systemic Sclerosis and Its Expression Is Positively Regulated by TGF-β: Epigenetic Feed-Forward Amplification of Fibrosis. Ghosh AK, Bhattacharyya S, Lafyatis R, Farina G, Yu J, Thimmapaya B, Wei J, Varga J. J Invest Dermatol. 2013 Jan 10. doi: 10.1038/jid.2012.479. PMID: 23303459.
TSLP upregulation in human SSc skin and induction of overlapping profibrotic genes and intracelullar signaling with IL-13 and TGFß. Christmann RB, Mathes A, Affandi AJ, Padilla C, Nazari B, Bujor AM, Stifano G, Lafyatis R. Arthritis Rheum. 2013 Jan 17. doi: 10.1002/art.37859. PMID: 23335246.
HLA-B35 and dsRNA induce endothelin-1 via activation of ATF4 in human microvascular endothelial cells. Lenna S, Chrobak I, Farina GA, Rodriguez-Pascual F, Lamas S, Lafyatis R, Scorza R, Trojanowska M. PLoS One. 2013;8(2):e56123. doi: 10.1371/journal.pone.0056123. Epub 2013 Feb 18.
Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. Lenna S, Farina AG, Martyanov V, Christmann RB, Wood TA, Farber HW, Scorza R, Whitfield ML, Lafyatis R, Trojanowska M. Arthritis Rheum. 2013 May;65(5):1357-66. doi: 10.1002/art.37891.
Thymic Stromal Lymphopoietin Is Up-Regulated in the Skin of Patients With Systemic Sclerosis and Induces Profibrotic Genes and Intracellular Signaling That Overlap With Those Induced by Interleukin-13 and Transforming Growth Factor β. Christmann RB, Mathes A, Affandi AJ, Padilla C, Nazari B, Bujor AM, Stifano G, Lafyatis R. Arthritis Rheum. 2013 May;65(5):1335-46. doi: 10.1002/art.37859.